Cytarabine sustained-release

Drug Profile

Cytarabine sustained-release

Alternative Names: cytarabine-liposomal; DepoCyt; DepoCyte; DepoFoam Encapsulated Cytarabine; DTC 101; NS-101; Savedar

Latest Information Update: 06 Mar 2017

Price : $50

At a glance

  • Originator SkyePharma Inc
  • Developer Mundipharma International; Pacira Pharmaceuticals; Scientific Institute San Raffaele
  • Class Antineoplastics; Arabinonucleosides; Pyrimidine nucleosides; Small molecules
  • Mechanism of Action DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Neoplastic meningitis
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Carcinomatous meningitis; Lymphomatous meningitis
  • Phase II B cell lymphoma
  • No development reported Neoplastic meningitis

Most Recent Events

  • 28 Feb 2017 Sigma-Tau Pharmaceuticals is now called Leadiant Biosciences
  • 15 Apr 2015 Phase-II clinical trials in B-cell lymphoma in Italy (Intrathecal) (NCT00801216)
  • 15 Apr 2015 Scientific Institute San Raffaele in collaboration with Mundipharma completes a phase II trial in B-cell lymphoma in Italy (NCT00801216)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top